An enlarged myomatous uterus is a uterus that has grown beyond its normal size because of uterine fibroids, which are benign smooth-muscle tumors also called leiomyomas. A normal uterus weighs roughly 60 to 80 grams and is about the size of a pear. Fibroids can push that weight past a kilogram and stretch the uterus to the size it would be at five or six months of pregnancy, sometimes larger. The enlargement itself is not a single disease but a downstream consequence of one or more fibroids accumulating bulk over time, and the symptoms, risks, and treatment decisions that follow depend heavily on how large the uterus has become and where the fibroids sit.
What Makes Fibroids Grow
Fibroids begin as a single mutated smooth-muscle cell in the uterine wall. That cell divides slowly over years, laying down enormous amounts of extracellular matrix, the dense scaffolding of collagen and other structural proteins that gives a fibroid its characteristic firmness. Estrogen and progesterone both promote this process by regulating the production of extracellular-matrix proteins and growth factors within the tumor.1Human Reproduction Update. Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics That hormonal dependence explains why fibroids virtually never appear before puberty, tend to grow during reproductive years, and usually shrink after menopause when estrogen and progesterone levels drop.
Genetics plays an equally important role. Roughly half to four-fifths of fibroids carry mutations in a gene called MED12, a component of the cell’s gene-regulation machinery.2PubMed. RISING STARS: Role of MED12 mutation in the pathogenesis of uterine fibroids These mutations are gain-of-function, meaning they actively push the cell toward abnormal behavior rather than simply disabling a brake. Fibroids carrying MED12 mutations tend to show up in multiples rather than as a solitary mass, and their gene-expression profiles ramp up collagen production and extracellular-matrix organization, which is part of why MED12-positive tumors can bulk up so aggressively.3PubMed Central. Engineered MED12 mutations drive uterine fibroid-like transcriptional and metabolic programs by altering the 3D genome compartmentalization A second genetic driver, HMGA2, accounts for many of the fibroids that lack MED12 mutations. The two pathways were once thought to be completely separate, but some fibroid nodules carry both a MED12 mutation and HMGA2 overexpression, suggesting the molecular story is more tangled than a clean two-track model.4Scientific Reports. Different DNA methylome, transcriptome and histological features in uterine fibroids with and without MED12 mutations
How Symptoms Change as the Uterus Enlarges
Small fibroids often produce no symptoms at all. As they grow and the uterus enlarges, the most common complaint is heavy menstrual bleeding. Fibroids interfere with the endometrium’s normal blood-vessel regulation: they reduce the production of vasoconstricting and clotting factors while boosting angiogenic signals, a combination that adds up to heavier, longer periods.5PubMed Central. Literature Review on the Role of Uterine Fibroids in Endometrial Function Over months or years, that blood loss can lead to iron-deficiency anemia, fatigue, and exercise intolerance.
Once the uterus reaches a certain size, bulk-related symptoms take over. Pressure on the bladder causes urinary frequency and urgency. Pressure on the rectum can cause constipation or a feeling of incomplete evacuation. Pelvic pain, back pain, and visible abdominal distension become part of daily life. These symptoms collectively erode quality of life, affecting work productivity, self-image, sexual function, and emotional well-being.6PubMed. Alternatives to hysterectomy: The burden of fibroids and the quality of life The burden is not trivial: the direct and indirect costs of fibroids are substantial for both the healthcare system and individual patients, spanning lost workdays, repeated imaging, multiple medication trials, and eventual surgery.7PubMed Central. Uterine Fibroids: Burden and Unmet Medical Need
When a Large Fibroid Uterus Becomes Dangerous
Most fibroids are medically benign and pose no immediate threat. But a significantly enlarged myomatous uterus can create complications that go well beyond heavy periods and bloating.
One underappreciated risk is venous thromboembolism. Large fibroids physically compress the pelvic veins, particularly the iliac veins, slowing blood flow and setting the stage for clot formation.8PubMed Central. Uterine Fibroids and Their Association with Acute and Chronic Venous Thromboembolic Disease-An Expert Review of the Literature A study of patients undergoing surgery for fibroids found that when the uterus weighed a kilogram or more, the rate of deep-vein thrombosis was roughly four times higher than in patients with smaller uteri.9PubMed. Deep-vein thrombosis is associated with large uterine fibroids In extreme cases, a fibroid large enough to compress the inferior vena cava can cause recurrent deep-vein thrombosis and pulmonary embolisms even in someone otherwise healthy. Treating the fibroid itself can break the cycle and, in some cases, allow the patient to stop long-term anticoagulation.10PubMed Central. A Complex Case of a Large Fibroid Uterus Compressing the Inferior Vena Cava Causing Recurrent Deep Vein Thrombosis and Pulmonary Embolisms
Urinary-tract obstruction is another serious concern. A very large fibroid can press on one or both ureters, the tubes connecting the kidneys to the bladder. If the obstruction goes unrecognized, it can cause hydronephrosis (swelling of the kidneys from backed-up urine) and progressive kidney damage. Case reports describe patients presenting with markedly elevated creatinine levels, new-onset hypertension, and severe bilateral hydronephrosis traced entirely to a large fibroid compressing the ureters.11PubMed Central. Bilateral Obstructive Uropathy From a Large Uterine Fibroid Causing Severe Renal Impairment: A Case Report These complications are uncommon, but they underscore why monitoring a growing fibroid uterus matters even when symptoms seem manageable.
Imaging and Ruling Out Something Worse
Ultrasound is the first-line imaging tool for fibroids and is sufficient in most straightforward cases. The worry that keeps clinicians up at night, though, is uterine sarcoma, a rare but aggressive cancer that can look like a benign fibroid on initial imaging. The odds of a presumed fibroid turning out to be a sarcoma are low, but distinguishing the two before surgery has real consequences for the type of procedure and urgency of treatment.
MRI is the best noninvasive tool for making that distinction. A systematic review and meta-analysis found that MRI achieved a pooled sensitivity of about 90% and specificity of about 96% for differentiating fibroids from sarcomas.12PubMed. Diagnostic accuracy of MRI in the differential diagnosis between uterine leiomyomas and sarcomas: A systematic review and meta-analysis Radiologists look at specific features: irregular borders, heterogeneous enhancement with poor blood flow in the center, high signal on certain sequences suggesting hemorrhage, invasion into the endometrial lining, and restricted diffusion on specialized sequences.13PubMed Central. Differentiating uterine sarcoma from leiomyoma: BET1T2ER check Conversely, a mass showing areas of uniformly low signal on standard MRI sequences and low or intermediate diffusion signal can be confidently called benign.14PubMed. Diagnostic Algorithm to Differentiate Benign Atypical Leiomyomas from Malignant Uterine Sarcomas with Diffusion-weighted MRI
MRI is also helpful in characterizing fibroid degeneration, a phenomenon that occurs when a fibroid outgrows its blood supply. The most dramatic type, red degeneration, happens most often during pregnancy. On MRI, the hallmark is a bright rim on certain sequences caused by thrombosed blood vessels at the fibroid’s periphery.15PubMed Central. Postpartum red degeneration of uterine leiomyoma: A diagnostic dilemma—A case report In a study of patients referred for uterine-artery embolization, about 5% had degenerating fibroids on MRI, and among those patients, a notable proportion had a recent pregnancy. Their symptoms ranged from pain and heavy bleeding to bulk complaints, and some had no symptoms at all.16PubMed Central. Degeneration of leiomyoma in patients referred for uterine fibroid embolization: incidence, imaging features and clinical characteristics Understanding these degeneration patterns on imaging prevents unnecessary emergency surgery when the real culprit is a fibroid going through a predictable, self-limiting transformation.
Medical Therapies to Shrink Fibroids
Because fibroids are hormone-driven, the first-line medical approach aims to suppress or modulate hormone signals. Older GnRH agonists (drugs like leuprolide) have been used for decades to temporarily shrink fibroids before surgery, but they induce a menopause-like state with hot flashes, bone loss, and mood changes, limiting their use to short courses.
A newer class, oral GnRH antagonists, has changed the landscape. Drugs in this category are taken once daily in combination with low-dose hormonal add-back therapy, which tamps down the worst menopausal side effects and protects bone density. A meta-analysis of five randomized trials found that patients treated with a GnRH antagonist were roughly five times more likely to achieve clinically meaningful bleeding control than patients on placebo, and fibroid volumes shrank by an average of about 27%.17PubMed Central. Efficacy of GnRH antagonists in the treatment of uterine fibroids: a meta-analysis Registration trials have shown that this bleeding control and bone-density preservation can be maintained for up to two years of continuous therapy.18PubMed Central. Use of oral GnRH antagonists combined therapy in the management of symptomatic uterine fibroids
These drugs are a genuine option for people who want to avoid or delay surgery, but they are not a cure. Fibroids tend to regrow once the medication is stopped. For someone with a massively enlarged uterus, a 27% volume reduction may bring meaningful symptom relief, but it rarely normalizes uterine size entirely. Medications work best as a bridge: buying time, controlling bleeding before a planned procedure, or managing symptoms in someone approaching menopause who hopes the fibroids will shrink on their own once hormones decline.
Uterine Artery Embolization
Uterine artery embolization (UAE) is a procedure in which an interventional radiologist threads a catheter into the arteries feeding the uterus and injects tiny particles to block blood flow to the fibroids. Starved of their blood supply, the fibroids shrink and soften over months. The Ontario Uterine Fibroid Embolization Trial reported a median uterine volume reduction of about 35% and a median dominant fibroid reduction of about 42%, along with significant relief from heavy menstrual bleeding.19PubMed. The Ontario Uterine Fibroid Embolization Trial. Part 2. Uterine fibroid reduction and symptom relief after uterine artery embolization for fibroids
A common concern is whether UAE works as well when the fibroid burden is very large. A study tracking long-term outcomes in patients with large fibroids, including dominant fibroids over 10 centimeters, found mean volume reductions of around 44% for both fibroids and the uterus. Clinical results were comparable to those in patients with smaller fibroids, and the rate of serious complications was not elevated.20PubMed Central. Uterine artery embolization in patients with a large fibroid burden: long-term clinical and MR follow-up There is even a modest correlation suggesting that larger fibroids respond with a proportionally greater volume reduction after embolization.21PubMed Central. Predicting the results of uterine artery embolization: correlation between initial intramural fibroid volume and percentage volume decrease
UAE preserves the uterus and requires no general anesthesia or abdominal incisions. Recovery is typically days rather than weeks. The main drawback is post-embolization syndrome, a few days of cramping, nausea, and low-grade fever as the fibroids undergo ischemic necrosis. UAE is generally not recommended for someone actively trying to become pregnant, because the long-term effects on fertility are still debated.
MRI-Guided Focused Ultrasound
For an even less invasive option, MRI-guided high-intensity focused ultrasound (MR-HIFU) uses concentrated ultrasound energy to heat and destroy fibroid tissue while the patient lies in an MRI scanner. The skin and tissue between the ultrasound source and the fibroid remain unharmed.22PubMed Central. Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MR-HIFU) in Treatment of Symptomatic Uterine Myomas For women who have not responded to medications and want to avoid both surgery and catheter-based procedures, this technology provides a safe, uterus-preserving alternative with rapid recovery.23PubMed Central. Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MRgHIFU) Treatment of Symptomatic Uterine Fibroids: An Evidence-Based Analysis Its main limitations are that very large or very numerous fibroids can make complete treatment in a single session impractical, and not all fibroid types absorb ultrasound energy well enough for effective ablation.
Surgery for Very Large Fibroid Uteri
When the uterus is extremely large, surgery remains the definitive treatment. Hysterectomy (removal of the uterus) is the only option that eliminates the possibility of fibroid recurrence. But for people who want to preserve fertility or simply keep their uterus, myomectomy (removing the fibroids while reconstructing the uterus) is the alternative, even in cases where the fibroid burden is massive.
Abdominal myomectomy for very large uteri is technically demanding. Blood loss tends to be higher, and about a quarter of patients in one large series needed transfusion. Repeat myomectomies carry significantly greater risk: one study found that mean blood loss nearly doubled and the rate of major complications jumped substantially in patients undergoing a second abdominal myomectomy compared to a first.24PubMed. Peri-operative morbidity associated with abdominal myomectomy for very large fibroid uteri Surgical teams use a range of techniques to control bleeding, including injecting vasoconstrictors directly into fibroids, making strategic incisions to avoid major blood vessels, and using intraoperative cell salvage to recapture and return lost blood to the patient.25Fertility and Sterility. Abdominal myomectomy in women with very large uterine size
Laparoscopic (keyhole) approaches are increasingly used even for large fibroids, but removing a bulky specimen through small incisions requires morcellation, cutting the tissue into small pieces inside the abdomen. After concerns that morcellation could spread undetected cancer cells in the rare case of a sarcoma masquerading as a fibroid, contained morcellation using a specimen bag became standard. Studies of contained morcellation report low spillage rates and no bag failures.26PubMed. Contained tissue extraction using power morcellation: prospective evaluation of leakage parameters 27PubMed Central. Power Morcellation Using a Contained Bag System Manual morcellation inside a bag is another option, with comparable safety and no need for powered cutting instruments.28PubMed Central. In-bag abdominal manual morcellation versus contained power morcellation in laparoscopic myomectomy: a comparison of surgical outcomes and costs
Parasitic Myomas After Morcellation
A rare but fascinating complication of morcellation deserves a mention because it catches many patients off guard. When fibroid tissue is cut into fragments for removal, small pieces can occasionally be left behind in the abdominal cavity. These fragments may attach to nearby structures like the omentum, bowel, or abdominal wall, develop a new blood supply from those tissues, and slowly grow into what are called parasitic myomas.29PubMed Central. Port site parasitic leiomyoma after laparoscopic myomectomy: a case report and review of the literature The reported incidence after laparoscopic morcellation ranges from roughly 0.1% to just under 1%.30Journal of Surgical Case Reports. Parasitic leiomyoma of the greater omentum: a case report and literature review These growths can be asymptomatic for years, discovered incidentally on imaging, or they can cause pain and bulk symptoms in unusual locations.31PubMed Central. Parasitic myoma after laparoscopic surgery: a mini-review Contained morcellation techniques were developed in part to reduce this risk.
Interestingly, parasitic myomas can also arise in people who have never had surgery. One theory is that a pedunculated fibroid hanging off the outside of the uterus can twist on its stalk, lose its uterine blood supply, and then tap into blood vessels from a nearby organ like the omentum to survive.32Journal of Surgical Case Reports. Parasitic leiomyoma of the greater omentum: a case report and literature review The phenomenon is rare in both surgical and non-surgical settings, but it complicates the diagnostic picture when an abdominal mass shows up in someone with a history of fibroids.
Fibroids and Fertility
Whether an enlarged myomatous uterus affects your ability to conceive depends on fibroid location more than total uterine size. Submucous fibroids, the ones that bulge into the uterine cavity, have the clearest association with reduced fertility and higher miscarriage rates, and removing them hysteroscopically improves outcomes.33Obstetrics, Gynaecology & Reproductive Medicine. Uterine fibroids: impact on fertility and pregnancy loss Intramural fibroids (the type that grows within the muscular wall) are a grayer area. Large intramural fibroids that distort the cavity are thought to impair implantation, but fibroids of the same size that sit in the outer wall may have minimal reproductive impact.
Pregnancy itself can change fibroid behavior. The hormone surge of early pregnancy occasionally triggers rapid growth or degeneration, as noted in the imaging section above. Red degeneration during pregnancy causes acute pain that usually resolves with conservative management, but it can mimic more dangerous conditions like placental abruption or appendicitis, making accurate diagnosis essential.
Environmental and Nutritional Risk Factors
Beyond hormones and genetics, environmental exposures and nutritional deficiencies appear to nudge fibroid risk. Endocrine-disrupting chemicals, substances found in plastics, pesticides, and industrial byproducts, have come under scrutiny because they can mimic or interfere with the body’s hormonal signaling. Epidemiologic studies have linked in-utero exposure to these chemicals with earlier fibroid diagnosis in adulthood, and animal models have shown increased fibroid incidence after developmental exposure.34PubMed Central. Endocrine-Disrupting Chemicals and Vitamin D Deficiency in the Pathogenesis of Uterine Fibroids
Vitamin D deficiency has emerged as another risk factor. Higher rates of deficiency are observed in populations that also carry a disproportionate fibroid burden, and lab studies suggest vitamin D may counteract some of the DNA damage and pro-inflammatory pathways triggered by endocrine disruptors in uterine stem cells.35PubMed Central. Vitamin D3 Ameliorates DNA Damage Caused by Developmental Exposure to Endocrine Disruptors in the Uterine Myometrial Stem Cells of Eker Rats These findings are still early-stage. Nobody has proven that correcting a vitamin D deficiency will stop fibroids from growing in a specific person. But the research adds to a picture in which fibroids are not purely a matter of genetic bad luck: environmental and nutritional context appears to matter.
Green Tea Extract as an Investigational Therapy
One of the more unexpected lines of fibroid research involves epigallocatechin gallate (EGCG), the main bioactive compound in green tea. A pilot randomized trial gave women with symptomatic fibroids either 800 mg of green tea extract per day or a placebo for four months. The placebo group saw fibroid volume increase by about 24%, while the treatment group saw a reduction of about 33%, along with a significant drop in symptom severity and improvement in quality of life.36PubMed Central. Treatment of symptomatic uterine fibroids with green tea extract: a pilot randomized controlled clinical study Lab work suggests EGCG targets fibrotic signaling pathways in fibroid cells, essentially dialing down the overproduction of collagen and extracellular matrix that makes fibroids dense and bulky.37Scientific Reports. Targeting fibrotic signaling pathways by EGCG as a therapeutic strategy for uterine fibroids
Enthusiasm should be tempered by the fact that this was a small, short trial. Larger confirmatory studies are ongoing, and EGCG’s safety profile at therapeutic doses over long periods still needs more data. Reviews describe it as a promising non-invasive option, particularly for managing symptoms and potentially slowing growth, but it is not yet a standard recommendation.38PubMed. The role of epigallocatechin gallate (EGCG) in uterine myomas For someone with a mildly enlarged uterus who is looking for low-risk adjunct strategies, it is worth discussing with a provider. For someone with a uterus the size of a six-month pregnancy, green tea extract is unlikely to be enough on its own.